Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1321-1340 of 1,694 trials

Preventing Relapses in Minimal Change Nephrotic Syndrome with Rituximab

We are studying whether Rituximab can help adults with Minimal Change Nephrotic Syndrome stay in remission after their first episode. This trial looks at the effectiveness and safety of the treatment over time.

Minimal Change Nephrotic Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNephrology

Ruxolitinib for Children with Hemophagocytic Lymphohistiocytosis

We are studying whether Ruxolitinib, combined with corticosteroids, can improve survival in children with HLH until they receive a stem cell transplant. The trial will also look at how well the treatment works and any side effects.

Haemophagocytic Lymphohistiocytosis in Children>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

Polycythemia Vera>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Pediatric Hepatic Tumor Trial: Evaluating Treatments for Hepatoblastoma and Hepatocellular Carcinoma

We are studying different treatment approaches for children with liver tumors to see which may improve outcomes and reduce side effects. This trial also aims to collect samples for future research on these cancers.

Liver Cancer (Hepatoblastoma and Hepatocellular Carcinoma)≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHepatologyOncology

Acute Myeloid Leukemia: Venetoclax vs. Intensive Chemotherapy

We are studying whether venetoclax with low-dose cytarabine can improve outcomes for patients with favorable risk acute myeloid leukemia compared to intensive chemotherapy. This trial will help us understand the best treatment options for this condition.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer Treatment: Fulvestrant with Palbociclib

We are studying whether combining fulvestrant with palbociclib helps postmenopausal women with hormone receptor-positive metastatic breast cancer live longer without disease progression compared to fulvestrant alone. This trial is for women who have completed at least five years of hormonal therapy and remained disease-free for over a year, or who have newly diagnosed metastatic disease.

Metastatic Breast Cancer1-2 yearsEfficacy phase (II)Standard MedicinesOncology

ANCA-Vasculitis: Corticosteroid Dosing Study

We are investigating if taking corticosteroids twice daily helps patients with ANCA-vasculitis maintain better blood sugar levels. This study will measure glucose control using continuous monitoring.

ANCA-associated VasculitisRapid-Progressive Glomerulonephritis≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyRheumatology

Advanced Breast Cancer: Inavolisib Treatment Study

We are studying a new treatment combining inavolisib with standard medications for patients with advanced hormone receptor-positive breast cancer. The goal is to see if this combination works better than a placebo in managing the disease.

Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

COPD Management: Azithromycin Based on Mucus Properties

We are studying whether prescribing azithromycin based on mucus rheology helps reduce COPD flare-ups compared to standard treatment. This trial aims to improve care for patients with chronic airway disease.

Chronic Obstructive Pulmonary Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicinePulmonology

Metastatic Colorectal Cancer: S 95005 with Bevacizumab

We are studying a new treatment combination for patients with metastatic colorectal cancer who cannot receive intensive therapy. The goal is to see if it helps patients live longer without disease progression compared to standard treatment.

Metastatic Colorectal Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

B-Cell Lymphoma: Valemetostat Tosylate Study

We are testing a new treatment for patients with relapsed or refractory B-cell lymphoma. The study aims to see how well it works and its safety across different lymphoma types.

Relapse/Refractory B-Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Stroke Prevention: ASPIRING Study

We are investigating if an oral antiplatelet drug can help prevent serious heart and brain events in stroke survivors. This study compares the effects of this medication to standard care without antiplatelet drugs.

Intracerebral Hemorrhage>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal MedicineNeurology

High-Risk Breast Cancer: Personalized Chemotherapy Study

We are investigating a new chemotherapy treatment for patients with high-risk, HER2-negative breast cancer to see if it improves survival rates compared to standard therapies. This trial is for individuals with specific genetic profiles, including those without known BRCA mutations.

Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pancreatic Cancer: Sotorasib with Chemotherapy

We are studying the safety of combining sotorasib with standard chemotherapy for patients with advanced pancreatic cancer that has a specific genetic mutation. This trial aims to see if this combination improves treatment outcomes.

Pancreatic Cancer≤3 monthsSafety phase (I)No PlaceboStandard MedicinesGastroenterologyOncology

B-Cell Malignancies: BGB-16673 Treatment Study

We are investigating the safety and effectiveness of BGB-16673 combined with other treatments for patients with relapsed or refractory B-cell malignancies. This study aims to find the best dose and assess how well the treatment works.

Relapsed or Refractory B-Cell Malignancies>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Acute Demyelinating Syndromes in Children: Azathioprine vs. Rituximab

We are studying whether starting treatment immediately with azathioprine or rituximab helps children with anti-MOG antibodies better than delaying treatment until a second attack. The goal is to see which method reduces relapses and improves health outcomes.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Hereditary Angioedema: Deucrictibant Tablet Study

We are evaluating a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The study aims to determine its effectiveness and safety compared to a placebo.

Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Hereditary Angioedema: Deucrictibant Extended-Release Tablet

We are studying a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The trial will evaluate its safety, effectiveness, and impact on quality of life.

Hereditary Angioedema>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Metastatic Thyroid Cancer: Personalized 131I Therapy

We are studying if a personalized approach to administering radioactive iodine can improve treatment outcomes for patients with metastatic thyroid cancer. This trial also looks at how genetic factors may affect treatment effectiveness.

Thyroid Cancer>2 yearsEfficacy phase (II)Standard MedicinesOncology

Fertility Preservation for Breast Cancer: Tamoxifen and Ovarian Stimulation

We are studying whether combining Tamoxifen with ovarian stimulation can help women with breast cancer collect healthy eggs before chemotherapy. This may support their chances of having children in the future.

Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology